摘要:
An extracorporeal method of treating a metabolic disorder comprising contacting a bodily fluid with (a) a hollow fiber membrane comprising a synthetic polymeric hemobiocompatible material; (b) a hollow fiber composite membrane comprising a carbonaceous material and a membrane-forming material; (c) a hollow fiber composite membrane comprising a carbonaceous material, an ion-exchange resin and a membrane-forming material, or (d) combinations thereof. A hollow fiber composite membrane comprising a micronized carbonaceous material and a membrane-forming material.
摘要:
An airtrap for a medical or physiological fluid in one embodiment includes a conical housing having a radius that increases from its top to its bottom when the housing is positioned for operation; a medical or physiological fluid inlet located at an upper portion of the conical housing; a medical or physiological fluid outlet located at a lower portion of the conical housing, the inlet and the outlet positioned and arranged so that medical or physiological fluid spirals in an increasing arc around an inside of the conical housing downwardly from the inlet to the outlet; and a gas collection area located at an upper portion of the conical housing. In another embodiment, the airtrap is shaped like a seahorse having a head section and a tail section. Any of the airtraps herein may be used for example in blood sets, peritoneal dialysis cassette tubing, and drug delivery sets.
摘要:
Surgical removal of tumors and other interventions are known to cause the acute release of malignant cells into the patient's bloodstream. These cells can implant at distant sites to cause metastatic disease. Described herein are devices and methods for selectively isolating and removing circulating tumor cells from the bloodstream. The device is implanted into the patient's vein or artery prior to surgery and can be removed at a suitable time point in the post-surgical period. The device may reside in the patient's body for many weeks if needed. In certain embodiments, the devices use a combination of mechanical isolation and targeted adhesion to filter and capture circulating malignant cells.
摘要:
A range of carbon materials can be produced using lignin in combination with synthetic phenolic resins or naturally occurring lingo-cellulosic materials. The lignin, which is essentially a naturally occurring phenolic resin, has a carbon yield on pyrolysis similar to that of the synthetic resins, which aids processing. The lignin can be used as a binder phase for synthetic resin or lignocellulosic materials allowing the production of monolithic carbons from a wide range of precursors, as the primary structural material where the thermal processing is modified by the addition of small quantities of synthetic resin materials or as structure modified in the production of meso/macro porous carbons in either bead, granular or monolithic form. A carbonised monolith is provided comprising mesoporous and/or macroporous carbon particles dispersed in a matrix of microporous carbon particles with voids between the particles defining paths for fluid to flow into and through the structure. The monolith may take the form of a shaped body having walls defining a multiplicity of internal transport channels for fluid flow, the transport channels being directed along the extrusion direction. The monolith may be made by carbonising a shaped phenolic body based on phenolic resin precursors. In a method for producing such a carbonisable shaped resin body solid particles of a first phenolic resin are provided which is partially cured so that the particles are sinterable but do not melt on carbonisation. The particles of the first phenolic resin are mixed with particles of a second phenolic resin that has a greater degree of cure than said first phenolic resin and has a mesoporous and/or macroporous microstructure that is preserved on carbonisation. The resulting mixture is formed into a dough e.g. by mixing the resin particles with methyl cellulose, PEO and water, after which the dough is extruded to form a shaped product and stabilising in its shape by sintering.
摘要:
La présente Invention concerne un support pour la purification d'un liquide biologique comprenant une phase solide sur laquelle sont greffées, par liaison covalente, des molécules d'au moins un oligosaccharide capable de se lier à un ou plusieurs anticorps,, ladite phase solide étant porteuse de fonctions aldéhyde -CHO libres, un procédé de production d'un tel support, l'utilisation d'un tel support dans la stabilisation de la liaison anticorps/oligosaccharide, ainsi qu'un procédé de purification d'un liquide biologique dans lequel le liquide biologique est mis en contact avec au moins un support selon l'Invention, de manière â obtenir la capture d'anticorps présents dans ledit liquide biologique par liaison(s) avec au moins certaines des molécules d'oligosaccharide(s) greffées sur la phase solide.
摘要:
A system and method for the practice of apheresis employs modules in the system which can be selected for a particular patient to treat particular situations or combinations of difficulties. In one example, Gal-3 mediates a large number of body reactions, and is an effective protector of tumor microenvironments and the like, as well inflammation driver. Removal of Gal-3 may make antic-cancer treatments, like photopheresis and TNF administration more effective. Separate modules, such as one for photopheresis and one for TNF receptor removal, may be combined with a module for the reduction of Gal-3, to render the combination of treatments each more effective than if administered alone.
摘要:
Die vorliegende Erfindung betrifft eine Vorrichtung zur Durchführung einer Apheresebehandlung, wobei die Vorrichtung einen extrakorporalen Kreislauf aufweist, in dem sich ein regenerierbarer Einfach-Adsorber zur Abtrennung von Substanzen aus Blut oder zur Abtrennung von Substanzen aus mittels eines Plasmaseparators gewonnenen Plasma befindet, wobei eine Leitung zur Führung des Blutes oder des Plasmas vorgesehen ist, die sich zu dem Adsorber erstreckt und über die der Adsorber mit Blut oder Plasma beaufschlagt wird, wobei ein Reservoir zur Aufnahme von Blut oder Plasma vorgesehen ist, das stromaufwärts des Adsorbers in der Leitung angeordnet ist oder stromaufwärts des Adsorbers mit der Leitung in Verbindung steht, und wobei ein Controller oder Schaltmittel vorgesehen ist, der/das derart ausgebildet ist, dass das Reservoir mit Blut oder Plasma befüllt wird und die Beaufschlagung des Adsorbers mit Blut oder Plasma unterbunden wird, wenn die Regeneration des Adsorbers durchgeführt wird.
摘要:
A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.
摘要:
본 발명에 의한 온도가변 투석액 재생 장치는 압축기, 응축기, 팽창기, 및 증발기를 갖는 Joule-Thomson 냉동기, 흡착제 칼럼, 및 투석액 사이에 열교환이 일어나는 투석액 열교환기를 혈액투석필터로부터 유출된 투석액의 온도를 조절하며, 이를 통해 투석액 내의 요독소와 노폐물을 제거할 수 있다. Joule-Thomson 냉동기는 2종 이상의 혼합 냉매를 사용함으로써 응축 및 증발 과정에서의 높은 잠열을 이용하여 투석액 온도를 신속하고 효율적으로 조절할 수 있다.
摘要:
A plasmapheresis device includes a column or other flow mechanism in which plasma flows following separation of the plasma from cellular components like blood cells, platelets and the like. The column includes a moiety, such as an antibody, which selectively binds to galectin-3. By removing galectin-3 from the blood stream of a mammal by at least 10%, improvements in the treatment of inflammation, suppression of the formation of fibroses, and a variety of cancer treatments can be effected or improved. The device provides for multiple columns to remove a variety of elements but includes one which selectively removes galectin-3 from the blood flow. Other agents may be added to the plasma before recombination with the cellular components of the blood, and before returning the recombined flow to the patient.